To study how Ripasudil can help for graft survival after corneal transplant
Phase 4
- Conditions
- Health Condition 1: H179- Unspecified corneal scar and opacity
- Registration Number
- CTRI/2024/06/069429
- Lead Sponsor
- Malvika Gokhale
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients who will undergo Penetrating Keratoplasty at Sankara Eye Hospital, Bangalore
Exclusion Criteria
1. Re-grafts
2. High risk grafts- Viral keratitis, Highly vascularized grafts
3. Pregnant women, Lactating mothers
4. Any posterior segment diseases
5. one eyed patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the graft clarity between the patients treated with Ripasudil & the control group during immediate postoperative periodTimepoint: 7 to 10 days postoperatively
- Secondary Outcome Measures
Name Time Method To analyze the effect of a Rho Kinase Inhibitor (Ripasudil) on endothelial cell functioning in post Penetrating keratoplasty patients using Specular microscopy & PachymetryTimepoint: 1 month, 3 months & 6 months postoperatively